3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
4
Neoplasms
3
Breast Neoplasms
3
Recurrence
2
Hypersensitivity
2
Fallopian Tube Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoadjuvant Therapy
1
Lung Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Docetaxel
277
Prednisone
237
enzalutamide
177
Leuprolide
172
Radiotherapy
164
Abiraterone Acetate
154
Magnetic Resonance Spectroscopy
147
bicalutamide
137
Goserelin
134
Androgen Antagonists
111
Radiosurgery
101
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
100
apalutamide
79
abiraterone
77
gallium 68 PSMA-11
74
Specimen Handling
67
darolutamide
58
Gonadotropin-Releasing Hormone
58
Radiation
56
Triptorelin Pamoate
53
cabazitaxel
50
Zoledronic Acid
49
pembrolizumab
48
Radiotherapy, Intensity-Modulated
47
Flutamide
47
Brachytherapy
47
luprolide acetate gel depot
46
Standard of Care
45
Carboplatin
44
Estramustine
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Prostatic Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT07268794
2025-12-08
CONVERT-HB1
Fudan University
Phase 2
Not yet recruiting
112 enrolled